Illumina to Announce Q1 Earnings with Positive Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy ILMN?
Source: seekingalpha
Illumina Inc (ILMN) saw a price increase of 5.19% as it crossed above its 5-day SMA, reflecting positive market conditions.
The company is set to announce its Q1 2023 earnings on April 30th, with consensus EPS estimates at $1.05, indicating an 8.2% year-over-year increase. This positive outlook is supported by Illumina's historical performance, where it has exceeded EPS and revenue estimates 88% of the time, enhancing investor confidence. However, there have been mixed revisions in estimates, suggesting a cautious sentiment in the market.
This upcoming earnings report is crucial for Illumina as it showcases the company's stable growth potential and competitive strength in the multiomics strategy, which could further influence its stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ILMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to rise
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 126.740
Low
40.50
Averages
133.54
High
170.00
Current: 126.740
Low
40.50
Averages
133.54
High
170.00
About ILMN
Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Illumina Reports Q1 Results Exceeding Revenue Expectations
- Performance Exceeds Expectations: Illumina's Q1 revenue reached $1.09 billion, reflecting a 4.8% year-on-year growth that surpassed analyst expectations of $1.07 billion, indicating strong performance in the genomics sector and potential for stock price appreciation.
- Profitability Improvement: The adjusted EPS was $1.15, exceeding the $1.05 consensus estimate by 9%, while adjusted operating income stood at $239 million with a 21.9% margin, showcasing the company's success in cost control and operational efficiency.
- Strong Clinical Demand: Clinical sequencing now accounts for over 65% of the company's consumables revenue, with more than 80 NovaSeq X instruments placed in the quarter, driving revenue growth and indicating sustained demand for high-throughput sequencing.
- Innovation-Driven Growth: Illumina plans to launch new high-throughput flow cells and spatial transcriptomics solutions to enhance the capabilities of the NovaSeq X platform, expected to further expand market share and strengthen competitive positioning.
See More
Illumina Q1 2026 Earnings Call Highlights
- Performance Exceeds Expectations: Illumina reported Q1 revenue of $1.09 billion, exceeding the midpoint of guidance by $20 million, primarily driven by strong instrument and clinical consumable sales, indicating sustained growth potential in clinical markets.
- Guidance Raised for the Year: Management raised the 2026 revenue outlook to $4.52 billion to $4.62 billion and non-GAAP EPS expectations to $5.15 to $5.30, reflecting confidence in future performance and robust market demand.
- Product Innovation Progress: Illumina launched TruPath and is on track to introduce its spatial transcriptomics offering later this year, showcasing the company's ongoing commitment to technological innovation aimed at solidifying its market leadership.
- Expanded Buyback Program: The company repurchased 2 million shares for approximately $242 million in Q1 and announced an additional $1.5 billion share repurchase program, demonstrating management's confidence in future growth and commitment to shareholders.
See More
Apple Beats Earnings Expectations, Roku Shares Surge 6%
- Apple's Strong Earnings: Apple reported fiscal Q2 earnings of $2.01 per share and revenue of $111.18 billion, surpassing analyst expectations of $1.95 and $109.66 billion, although iPhone sales missed estimates for the third consecutive quarter, indicating robust competitiveness in the overall market.
- Roku's Impressive Performance: Roku's Q1 revenue reached $1.25 billion, exceeding the expected $1.20 billion, with adjusted EBITDA of $148.4 million also above the $131.3 million forecast, and the company anticipates continued outperformance in upcoming quarters, highlighting its growth potential in the streaming market.
- Twilio's Strong Rebound: Twilio reported Q1 adjusted earnings of $1.50 per share, beating the $1.27 estimate, with revenue of $1.41 billion also exceeding the $1.34 billion expectation, showcasing sustained growth and strong market demand in the cloud communications sector.
- GoDaddy's Excellent Results: GoDaddy's Q1 earnings were $1.60 per share on revenue of $1.27 billion, both surpassing analyst expectations of $1.52 and $1.26 billion, while free cash flow of $473.6 million exceeded the anticipated $454.2 million, indicating strong competitiveness and profitability in the website building market.
See More
Illumina Set to Announce Q1 Earnings with Positive Estimates
- Earnings Announcement Date: Illumina (ILMN) is set to release its Q1 2023 earnings on April 30th after market close, with consensus EPS estimates at $1.05, reflecting an 8.2% year-over-year increase, and revenue estimates at $1.07 billion, indicating a 2.9% year-over-year growth, showcasing the company's stable growth potential in the market.
- Historical Performance Review: Over the past two years, Illumina has exceeded EPS and revenue estimates 88% of the time, demonstrating reliability in profitability and market performance, which enhances investor confidence in the stock.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and ten downward revisions, while revenue estimates experienced seven upward revisions and one downward revision, reflecting a cautious market sentiment regarding the company's future performance.
- Long-Term Growth Outlook: Illumina's revenue guidance for 2026 is set between $4.5 billion and $4.6 billion, indicating ongoing advancements in clinical growth and multiomics strategy, which suggests significant future growth potential and competitive strength in the market.
See More
Illumina Launches DRAGEN v4.5 Software Enhancing Genomic Analysis
- Software Capability Expansion: Illumina's launch of DRAGEN v4.5 significantly enhances genomic analysis capabilities, improving variant detection accuracy through expanded pangenome representation and personalization, thereby empowering discoveries in rare diseases and oncology research.
- Machine Learning Application: The new version employs machine learning to address noise issues in formalin-fixed paraffin-embedded (FFPE) samples, successfully reducing false positives for single nucleotide variants by over 90%, thus enhancing sensitivity without increasing computational burden, ensuring reliable detection of biologically relevant variants in complex samples.
- Oncovirus Detection: DRAGEN v4.5 introduces robust oncovirus detection capabilities, with internal tests showing 100% detection of expected oncoviruses and identification of 18 additional strains, showcasing its sensitivity for high-risk HPV and Epstein-Barr Virus, providing new avenues for research into oncovirus-driven cancers.
- Clinical Application Prospects: Researchers applying DRAGEN v4.5 to acute myeloid leukemia (AML) samples found its integration of variant detection and methylation analysis improves relapse risk predictions, highlighting the software's significant potential in clinical research applications.
See More
Illumina Launches DRAGEN v4.5 Software Enhancing Genomic Analysis
- Software Capability Expansion: Illumina's launch of DRAGEN v4.5 significantly enhances analytical capabilities for complex genomic regions and sample types, particularly in rare disease and oncology research, improving the accuracy and efficiency of biological signal extraction.
- Personalization and Machine Learning: The new version reduces false positives and negatives in small variant calling by approximately 20% through default personalization, while introducing machine learning-driven somatic analysis that enhances sensitivity in tumor samples, enabling researchers to better identify biologically relevant variants.
- Multiomic Analysis Capability: DRAGEN v4.5 expands multiomic analysis with structural variant calling, integrated with Illumina's 5-base solution, providing comprehensive genetic and epigenetic insights that advance research into complex cancer issues.
- Global Genomic Diversity: The addition of Middle Eastern reference genomes improves mapping and variant calling across global population diversity, addressing known underdiagnosis issues in certain populations, thereby enhancing the software's application value.
See More
Illumina Reports Q1 Results Exceeding Revenue Expectations
- Performance Exceeds Expectations: Illumina's Q1 revenue reached $1.09 billion, reflecting a 4.8% year-on-year growth that surpassed analyst expectations of $1.07 billion, indicating strong performance in the genomics sector and potential for stock price appreciation.
- Profitability Improvement: The adjusted EPS was $1.15, exceeding the $1.05 consensus estimate by 9%, while adjusted operating income stood at $239 million with a 21.9% margin, showcasing the company's success in cost control and operational efficiency.
- Strong Clinical Demand: Clinical sequencing now accounts for over 65% of the company's consumables revenue, with more than 80 NovaSeq X instruments placed in the quarter, driving revenue growth and indicating sustained demand for high-throughput sequencing.
- Innovation-Driven Growth: Illumina plans to launch new high-throughput flow cells and spatial transcriptomics solutions to enhance the capabilities of the NovaSeq X platform, expected to further expand market share and strengthen competitive positioning.
See More
Illumina Q1 2026 Earnings Call Highlights
- Performance Exceeds Expectations: Illumina reported Q1 revenue of $1.09 billion, exceeding the midpoint of guidance by $20 million, primarily driven by strong instrument and clinical consumable sales, indicating sustained growth potential in clinical markets.
- Guidance Raised for the Year: Management raised the 2026 revenue outlook to $4.52 billion to $4.62 billion and non-GAAP EPS expectations to $5.15 to $5.30, reflecting confidence in future performance and robust market demand.
- Product Innovation Progress: Illumina launched TruPath and is on track to introduce its spatial transcriptomics offering later this year, showcasing the company's ongoing commitment to technological innovation aimed at solidifying its market leadership.
- Expanded Buyback Program: The company repurchased 2 million shares for approximately $242 million in Q1 and announced an additional $1.5 billion share repurchase program, demonstrating management's confidence in future growth and commitment to shareholders.
See More
Apple Beats Earnings Expectations, Roku Shares Surge 6%
- Apple's Strong Earnings: Apple reported fiscal Q2 earnings of $2.01 per share and revenue of $111.18 billion, surpassing analyst expectations of $1.95 and $109.66 billion, although iPhone sales missed estimates for the third consecutive quarter, indicating robust competitiveness in the overall market.
- Roku's Impressive Performance: Roku's Q1 revenue reached $1.25 billion, exceeding the expected $1.20 billion, with adjusted EBITDA of $148.4 million also above the $131.3 million forecast, and the company anticipates continued outperformance in upcoming quarters, highlighting its growth potential in the streaming market.
- Twilio's Strong Rebound: Twilio reported Q1 adjusted earnings of $1.50 per share, beating the $1.27 estimate, with revenue of $1.41 billion also exceeding the $1.34 billion expectation, showcasing sustained growth and strong market demand in the cloud communications sector.
- GoDaddy's Excellent Results: GoDaddy's Q1 earnings were $1.60 per share on revenue of $1.27 billion, both surpassing analyst expectations of $1.52 and $1.26 billion, while free cash flow of $473.6 million exceeded the anticipated $454.2 million, indicating strong competitiveness and profitability in the website building market.
See More
Illumina Set to Announce Q1 Earnings with Positive Estimates
- Earnings Announcement Date: Illumina (ILMN) is set to release its Q1 2023 earnings on April 30th after market close, with consensus EPS estimates at $1.05, reflecting an 8.2% year-over-year increase, and revenue estimates at $1.07 billion, indicating a 2.9% year-over-year growth, showcasing the company's stable growth potential in the market.
- Historical Performance Review: Over the past two years, Illumina has exceeded EPS and revenue estimates 88% of the time, demonstrating reliability in profitability and market performance, which enhances investor confidence in the stock.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and ten downward revisions, while revenue estimates experienced seven upward revisions and one downward revision, reflecting a cautious market sentiment regarding the company's future performance.
- Long-Term Growth Outlook: Illumina's revenue guidance for 2026 is set between $4.5 billion and $4.6 billion, indicating ongoing advancements in clinical growth and multiomics strategy, which suggests significant future growth potential and competitive strength in the market.
See More
Illumina Launches DRAGEN v4.5 Software Enhancing Genomic Analysis
- Software Capability Expansion: Illumina's launch of DRAGEN v4.5 significantly enhances genomic analysis capabilities, improving variant detection accuracy through expanded pangenome representation and personalization, thereby empowering discoveries in rare diseases and oncology research.
- Machine Learning Application: The new version employs machine learning to address noise issues in formalin-fixed paraffin-embedded (FFPE) samples, successfully reducing false positives for single nucleotide variants by over 90%, thus enhancing sensitivity without increasing computational burden, ensuring reliable detection of biologically relevant variants in complex samples.
- Oncovirus Detection: DRAGEN v4.5 introduces robust oncovirus detection capabilities, with internal tests showing 100% detection of expected oncoviruses and identification of 18 additional strains, showcasing its sensitivity for high-risk HPV and Epstein-Barr Virus, providing new avenues for research into oncovirus-driven cancers.
- Clinical Application Prospects: Researchers applying DRAGEN v4.5 to acute myeloid leukemia (AML) samples found its integration of variant detection and methylation analysis improves relapse risk predictions, highlighting the software's significant potential in clinical research applications.
See More
Illumina Launches DRAGEN v4.5 Software Enhancing Genomic Analysis
- Software Capability Expansion: Illumina's launch of DRAGEN v4.5 significantly enhances analytical capabilities for complex genomic regions and sample types, particularly in rare disease and oncology research, improving the accuracy and efficiency of biological signal extraction.
- Personalization and Machine Learning: The new version reduces false positives and negatives in small variant calling by approximately 20% through default personalization, while introducing machine learning-driven somatic analysis that enhances sensitivity in tumor samples, enabling researchers to better identify biologically relevant variants.
- Multiomic Analysis Capability: DRAGEN v4.5 expands multiomic analysis with structural variant calling, integrated with Illumina's 5-base solution, providing comprehensive genetic and epigenetic insights that advance research into complex cancer issues.
- Global Genomic Diversity: The addition of Middle Eastern reference genomes improves mapping and variant calling across global population diversity, addressing known underdiagnosis issues in certain populations, thereby enhancing the software's application value.
See More
